Your session is about to expire
← Back to Search
Other
SPH5030 tablets for Solid Tumors
Phase < 1
Recruiting
Led By Binghe Xu
Research Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Summary
To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors
Eligible Conditions
- Solid Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Dose-limiting toxicity (DLT)
Maximum tolerated dose(MTD)
Number of patients with adverse events
Secondary study objectives
6-month Progression-free Survival (6mPFS)
Accumulation ratio of area under the serum concentration-time curve (Rac_AUC) of the Dosing Interval (0-14D) of SPH5030
Accumulation ratio of maximum serum concentration (Rac_Cmax) of SPH5030
+14 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: SPH5030 tabletsExperimental Treatment1 Intervention
Subjects will take SPH5030 tablets orally on an empty stomach once or twice a day.
Each subject will receive only one corresponding dose, and there were five dose groups: 50mg/ d, 100mg/ d, 200mg/ d, 300mg/ d and 400mg/ d.
Find a Location
Who is running the clinical trial?
Shanghai Pharmaceuticals Holding Co., LtdLead Sponsor
41 Previous Clinical Trials
5,203 Total Patients Enrolled
Binghe XuPrincipal InvestigatorCancer Institute and Hospital, Chinese Academy of Medical Sciences
14 Previous Clinical Trials
6,093 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger